Computational flow cytometry immunophenotyping at diagnosis is

² unable to predict relapse in childhood B-cell Acute Lymphoblastic

3 Leukemia

- ⁴ Álvaro Martínez-Rubio^{1,2,*}, Salvador Chulián^{1,2}, Ana Niño-López^{1,2}, Rocío Picón-González^{1,2}, Juan F.
- ⁵ Rodríguez Gutiérrez³, Eva Gálvez de la Villa³, Teresa Caballero Velázquez⁴, Águeda Molinos
- ⁶ Quintana⁴, Ana Castillo Robleda^{5,6}, Manuel Ramírez Orellana^{5,6,7}, María Victoria Martínez Sánchez^{8,9},
- 7 Alfredo Minguela Puras^{8,9}, José Luis Fuster Soler^{9,10}, Cristina Blázquez Goñi^{2,4}, Víctor M.
- 8 Pérez-García¹¹, and María Rosa^{1,2}
- 9 ¹Department of Mathematics, University of Cádiz, 11510 Puerto Real, Spain
- ¹⁰ ²Biomedical Research and Innovation Institute of Cádiz (INiBICA), Puerta del Mar University Hospital, 11009 Cádiz, Spain
- ¹¹ ³Department of Paediatric Hematology and Oncology, Jerez Hospital, 11407 Jerez de la Frontera, Spain
- ⁴Department of Hematology, Virgen del Rocío University Hospital, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad
- 13 de Sevilla, 41013 Sevilla, Spain
- 14 ⁵Oncohematology Unit, Niño Jesús University Children's Hospital, 28009 Madrid, Spain
- 15 ⁶Foundation for Biomedical Research Niño Jesús University Children's Hospital, 28009 Madrid, Spain
- 16 ⁷Health Research Institute La Princesa, 28009 Madrid, Spain
- 17 ⁸Immunology Service, Clinical University Hospital Virgen de la Arrixaca, 30120 Murcia, Spain
- 18 ⁹Instituto Murciano de Investigación Sanitaria (IMIB), University of Murcia, 30120 Murcia, Spain
- ¹⁰ Department of Pediatric Hematology and Oncology, Clinical University Hospital Virgen de la Arrixaca, 30120 Murcia, Spain
- 20 ¹¹Mathematical Oncology Laboratory (MOLAB), Departament of Mathematics, Instituto de Matemática Aplicada a la Ciencia y la
- 21 Ingeniería, Universidad de Castilla-La Mancha, Ciudad Real, Spain.
- 22 *Correspondence: alvaro.martinezrubio@uca.es

23

24 SUMMARY

B-cell Acute Lymphoblastic Leukemia is the most prevalent form of childhood 25 cancer, with approximately 15% of patients undergoing relapse after initial 26 treatment. Further advancements depend on novel therapies and more precise 27 risk stratification criteria. In the context of computational flow cytometry and 28 machine learning, this paper aims to explore the potential prognostic value of 29 flow cytometry data at diagnosis, a relatively unexplored direction for relapse 30 prediction in this disease. To this end, we collected a dataset of 252 patients 31 from three hospitals and implemented a comprehensive pipeline for 32 multicenter data integration, feature extraction, and patient classification, 33 comparing the results with existing algorithms from the literature. The analysis 34 revealed no significant differences in immunophenotypic patterns between 35 relapse and non-relapse patients and suggests the need for alternative 36 approaches to handle flow cytometry data in relapse prediction. 37

38 INTRODUCTION

B-cell progenitor Acute Lymphoblastic Leukemia (BCP-ALL) stands as the most
 prevalent pediatric cancer, impacting approximately 40,000 children globally each
 year. Recent clinical trials report survival rates exceeding 90%¹. However, the
 remaining 15% experience relapse or refractory disease, with this subset facing a
 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
 significantly worse prognosis². The advancements in overall survival over the past

decades can be attributed to the implementation of intensive multi-agent 44 chemotherapy regimens tailored to specific risk groups. These groups are identified 45 through cytomorphology, molecular biology, cytogenetics, and immunology³. Despite 46 these strides, the latest data suggests that improvements in overall survival will not 47 be reached by further adjusting regimes or incorporating novel chemotherapeutic 48 Instead, hopes for finally achieving a manageable disease lie in agents. 49 immunotherapies for relapsed patients and refined risk stratification criteria at 50 diagnosis⁴. New strategies are therefore necessary to identify and select patients 51 unresponsive to standard chemotherapy and who are at a heightened risk of relapse, 52 given the inaccuracies of current risk allocation schemes⁵. 53

Quantitation of minimal residual disease levels early during therapy, either by flow 54 cytometry (FC) or by clonospecific qPCR, has been consistently reported as a major 55 prognostic factor^{6,7}. Despite the fact that FC generates an extensive dataset of 56 single-cell information, it is currently not utilized in risk stratification. In other words, 57 the immunophenotype of the leukemic clone at diagnosis lacks prognostic value. 58 Several factors impede the comprehensive exploitation of this type of data. One of 59 them is the inherent challenge of managing high-dimensional data, especially in the 60 clinical setting⁸. Another reason is the difficulty in gathering a sufficiently large 61 retrospective cohort of patients. Indeed, the lack of prognostic value means that they 62 are less frequently published than other clinical and pathologic information and 63 Lastly, despite ongoing efforts to standardize therefore stored more casually. 64 instruments and protocols^{9,10}, differences in adherence to standards, cytometer 65 settings, and calibration continue to pose significant challenges for multicenter data 66 integration¹¹. 67

The recent emergence of computational flow cytometry¹² has paved the way for 68 automated and more thorough analyses of this type of data. This interdisciplinary 69 field brings together flow cytometry with modern pattern recognition and statistical 70 techniques for data processing and analysis. In combination with machine learning, 71 these techniques can be applied for survival or relapse prediction, sample 72 classification, or subpopulation detection¹³. Surprisingly, there is a notable lack of 73 applications of these tools in the context of BCP-ALL, with only a few published 74 works. For instance, a study by Reiter et al.¹⁴ gathered a dataset of 337 bone marrow 75 samples and employed supervised machine learning to automate minimal residual 76 disease assessment on day +15. Good et al.¹⁵ compiled data from 54 patients and 77 developed a classifier that organized cells based on developmental stage and 78 achieved a high accuracy in relapse prediction¹⁵. Two additional preliminary works 79 from our group complete this landscape^{16,17}, one based on percentile differences of 80 marker expression and the other on topological data analysis. 81

In this work, we set out to fill this gap and determine whether standard flow cytometry panels at the time of diagnosis contain prognostic information. To this end we collected the largest database of FC data of children with BCP-ALL for a computational analysis yet. We integrated tools from computational flow cytometry for data preprocessing and normalization and designed a comprehensive pipeline for

feature extraction and classification. We identified cellular subpopulations across the 87 cohort of patients and we assessed the prognostic value of cell abundance and 88 marker expression with a variety of metrics. We additionally contrasted and 89 confirmed our results with other algorithms for biomarker discovery already presented 90 in the literature. Contrary to our initial hypothesis, our results dismiss the utility of 91 differential expression and distribution-based feature engineering for FC-based 92 We conclude the study by offering insights into the absence of classification. 93 discernible differences between relapse and non-relapse patients and proposing 94 potential avenues for further exploration in this line of research. 95

96 **RESULTS**

97 Patient cohort is representative of childhood BCP-ALL population

We collected data from 252 patients from three hospitals, diagnosed between 2011 98 and 2022. Risk stratification criteria, treatment protocols, and outcomes are detailed 99 in the 'Methods' section. Table S1 shows their clinicopathologic characteristics. The 100 full cohort presents a relapse rate of 17,5%, in line with recent world-wide reports¹⁸. 101 Most patients present a common immunophenotype and belong to the intermediate 102 risk group. The frequency of genetic alterations is also within common ranges reported 103 in European countries¹⁹. After preprocessing and filtering (see 'Methods' and Figure 104 S1), 188 patients were retained for analysis. Their clinicopathologic characteristics 105 are shown in Table 1. The only relevant differences with respect to the full cohort are 106 a lower proportion of high-risk patients (2.7% VS 4.0%) and a higher percentage of 107 relapse patients (20.2% VS 17.5%), still within reported ranges. 108

Normalization and merging allows integration of multi-center, multi-sample flow cytometry data

The cornerstone of the study is FC data at diagnosis. The joint analysis of multicenter 111 data presents several challenges that needed to be addressed prior to the 112 classification part of the study. Although FC panels for BCP-ALL are now 113 standardized¹⁰, we needed to account for differences arising from the use of different 114 cytometers, changes in machine calibration with time and other batch effects. 115 Furthermore, due to the maximum number of fluorochromes that can be used in a 116 single experiment, each patient's sample is split in different tubes or aliquots that 117 needed to be integrated if all protein markers were to be analysed together. 118

These sources of inter-center and inter-aliquot heterogeneity were addressed here by means of a modified min-max transformation and a quantile normalization step (Figure S2, see 'Methods'). As for the combination of several FC files into a single file, various methods have already been developed, relying mostly on nearest neighbor imputation and clustering-based imputation. In order to choose the most suitable method we used the Earth Mover Distance (EMD) to compare the distribution of a marker in the original tube versus the imputed file²⁰, following a recent review on

	Dataset 1 (HVR)	Dataset 2 (HVA)	Dataset 3 (HNJ)	Total
	(N=46)	(N=47)	(N=95)	(N=188)
Sex - no. (%)				
Male	27 (58.7)	24 (51.1)	44 (46.3)	95 (50.5)
Female	19 (41.3)	23 (48.9)	51 (53.7)	93 (49.5)
Age at diagnosis - yr				
Median	3	5	4	4
Range	0 - 13	0 - 15	0 - 16	0 - 16
Long term status -no. (%)				
Relapse	11 (23.9)	4 (8.5)	23 (24.2)	38 (20.2)
No relapse	35 (76.1)	43 (91.5)	72 (75.8)	150 (79.8)
Immunophenotype - no. (%)				
Common	29 (63.0)	36 (76.6)	88 (92.6)	153 (81.4)
Pre-B	14 (30.4)	9 (19.1)	4 (4.2)	27 (14.4)
Pro-B	2 (4.3)	2 (4.3)	3 (3.2)	7 (3.7)
Mixed	1 (2.2)	0 (0)	0 (0)	1 (0.5)
Bone Marrow blasts				
at diagnosis - %				
Median	80.4	78.8	85.0	81.7
Range	10.0 - 96.3	25.6 - 95.0	30.0 - 99.0	10.0 - 99.0
Leukocytes - cell/nL				
Median	8.29	7.16	11.07	8.61
Range	1.61 - 214.21	0.54 - 336.19	0.21 - 294.0	0.21 - 336.19
Central Nervous System				
involvement - no. (%)				
Yes	2 (4.3)	2 (4.3)	10 (10.5)	14 (7.4)
No	44 (95.7)	45 (95.7)	85 (89.5)	174 (92.6)
Risk at diagnosis - no. (%)				
High	1 (2.2)	3 (6.4)	1 (1.1)	5 (2.7)
Intermediate	20 (43.5)	24 (51.1)	76 (80.0)	120 (63.9)
Low	25 (54.3)	20 (42.5)	18 (18.9)	63 (33.4)
Karyotype - no. (%)				
High hyperdiploidy (>50)	12 (26.2)	2 (4.2)	12 (12.6)	26 (13.8)
Hyperdiploidy (47-50)	3 (6.5)	1 (2.1)	10 (10.5)	14 (7.4)
Normal (46)	16 (34.8)	7 (14.9)	40 (42.1)	63 (33.5)
Hypodiploidy (40-45)	2 (4.3)	0 (0)	5 (5.3)	7 (3.7)
Low hypodiploidy (<40)	1 (2.2)	0 (0)	0 (0)	1 (0.6)
No metaphases	11 (24.0)	6 (12.8)	26 (27.4)	43 (22.9)
No information	1 (2.2)	31 (66.0)	2 (2.1)	34 (18.1)
Chromosomic alterations - no. (%)				
ETV6/RUNX1 t(12;21)	7 (15.2)	10 (21.3)	24 (25.2)	41 (21.8)
TCF3/PBX1 t(1;19)	1 (2.2)	1 (2.1)	4 (4.2)	6 (3.2)
MLL rearrangement	4 (8.7)	1 (2.1)	1 (1.1)	6 (3.2)
BCR/ABL1 t(9;22)	0 (0)	0 (0)	2 (2.1)	2 (1.1)
No alterations	32 (69.6)	34 (72.3)	63 (66.3)	129 (68.6)
No information	2 (4.3)	1 (2.1)	1 (1.1)	4 (2.1)

Table 1. Summary of clinicopathologic characteristics of patients retained for analysis. HVR = Virgen del Rocío Hospital, HVA = Virgen de la Arrixaca Hospital, HNJ = Niño Jesus Hopital.

the topic²¹. We compared the basic approach²² (direct nearest neighbor imputation) 126 with the algorithms cytoBackBone²³ (non-ambiguous nearest neighbor imputation), 127 CYTOFmerge²⁴ (median of 50 nearest neighbor imputation) and cyCombine²⁵ 128 (imputation by drawing from probability density estimates). Figure 1A shows the EMD 129 of all patients for each method and each marker. Ideally, the merged marker would 130 display the same distribution as the actual measurements. Figures 1B and 1C show 131 the tradeoff between merging quality, number of cells per aliguots and runtime. The 132 conclusion was that the basic approach (direct nearest neighbor imputation) 133

performed better and faster than the other methodologies, preserving the maximum
number of cells. CyCombine and cytoBackBone performed similarly, with longer
computation time associated with the removal of ambiguous cells. The conclusions
were the same across hospitals (Figures S3 and S4). In the light of this result, we
chose to continue the analysis with the basic approach and repeat it with the
cyCombine method in order to confirm the stability of the results.



Figure 1. Comparison of file merging methods. A. Boxplots summarizing the distributions of Earth's Mover Distance (EMD) for each marker. The box includes median (horizontal line) and interquartile range (IQR). **B.** Dots represents the runtime for each patient, with the x-axis displaying the number of cells per patient. Marker size represents the ratio between the number of cells to merge and the number of cells in the resulting file. Inset displays accumulated computation time for the complete cohort. **C.** Comparison between average EMD and runtime per cell. Marker size represents the ratio between the number of cells to merge and the number of cells to merge and the number of cells in the resulting file, averaging all patients. Patients analysed here belong to hospital HNJ. Similar results are obtained for hospitals HVA and HVR (Figures S3 and S4).

Clustering and dimensionality reduction techniques reveal common structureand subpopulations across patients

After preprocessing, file merging and patient selection, the final set of FC markers 142 included B-cell markers CD19, CD10 and CD20; pan-leukocyte markers CD45 and 143 CD38; hematopoietic stem cell marker CD34 and myeloid markers CD58 and CD66c. 144 The next step was to visualize the structure of the bone marrow of all patients. Cell 145 subpopulations can be obtained by means of clustering techniques, which replace the 146 traditional manual analysis or 'gating'²⁶. Here, we pooled all the files together and 147 clustered via FlowSOM²⁷. This algorithm produces a low dimensional visualization of 148 the structure of the data in two steps. Firstly, it clusters on a higher resolution, which 149 we manually set to 50 clusters (the influence of this number of clusters on the results 150 will be explored later). Secondly, it obtains an optimal lower number of metaclusters 151 by aggregating with consensus clustering. It then creates a minimum spanning tree 152 visualization in which each cluster is represented by a node, and similar clusters are 153 linked. This is shown in Figure 2. Marker expression per cluster is shown in Figure 154 2A, while Figure 2B represents the metacluster to which each cluster belongs. Each 155 metacluster is identified with a cell subpopulation that can be manually annotated. The 156 number of patients that contribute to each cluster is shown in Figure 2C, split in relapse 157 (R) and non-relapse patients (NR). 158

To visualize the clustering information on a single-cell level we used UMAP. This 159 dimensionality reduction technique computes a two-dimensional representation that 160 preserves the structure of the cell subpopulations²⁸. The result is shown in Figure 2D. 161 Each cell is colored according to FlowSOM metacluster. For comparison, the marker 162 expression of each region of the UMAP embedding is shown in Figure 2E. We note 163 that both FlowSOM and UMAP yield a similar structure, as shown by the proximity of 164 the different metaclusters and UMAP regions. FlowSOM obtained an optimal number 165 of 8 metaclusters. There were two main metaclusters (1 and 2) that comprised most 166 of the CD19+ cells and that we identified with the leukemic clone. These are immature 167 B-cells with intermediate expression of CD45 and heterogeneous expression of CD34 168 and CD38. The two metaclusters were distinguished by relative expression of CD66c. 169 We also assigned metacluster 6 to the leukemic cell population, distinguished from 170 the other two by a negative expression of CD10. These metaclusters contained the 171 majority of cells since the bone marrow of BCP-ALL patients at diagnosis are almost 172 fully invaded. Metacluster 8, with a high expression of CD45 and CD20, represents 173 healthy, mature B-cells. The remaining metaclusters represent other bone marrow 174 cell types, including T-cells with high expression of CD45 (metacluster 7) and myeloid 175 subpopulations (metaclusters 3, 4 and 5). While these subpopulations are seldom 176 considered in B-cell malignancies, here we also explored them for prognostic value. 177 With respect to the robustness and generality of these results, we note that most of the 178 clusters contained more than 80% of the patients. When considering the metacluster 179 scale, virtually all patients contribute to all cell subpopulations, with the exception of the 180 minor myeloid subpopulations (metacluster 4). This confirmed that all patients adhere 181 to the global structure described in this section. 182



Figure 2. Clustering and visualization of flow cytometry data. A. Minimum spanning tree generated by FlowSOM. Each node represents a cluster, and similar clusters are linked. Pie plot represent the relative expression of protein markers within each cluster. **B.** Minimum spanning tree generated by FlowSOM. Color denotes the metacluster to which each cluster belongs. **C.** Number of patients per cluster colored according to outcome (R=relapse, NR=non-relapse). Clusters are sorted according to the metacluster they belong to (vertical bar on the left). Vertical dashed line represents the maximum amount of patients. **D.** Single-cell UMAP embedding. Each cell is colored according to relative marker expression.

183 Individual patient cells per cluster are unable to predict relapse

Figure 2C shows that only a number of clusters contain a proportion of relapse patients above the baseline 20%, without any particular cluster being dominated by either relapse or non-relapse patients. To investigate the predictive power of cell abundance per cluster, however, we had to check not only the number of patients but also how many cells each patient contributed with. The idea was to test if relapse patients tended to participate more in a subset of clusters, or if instead all patients contributed equally. To do so, we calculated the percentage of cells per cluster for



Figure 3. Results of abundance-based classification. A. Comparison of cell percentage per cluster between relapse (R) and non-relapse (NR) patients. Boxplot includes median and IQR. The scale has been transformed with an inverse hyperbolic sine for clarity. Black box and asterisk denote clusters with significant differences in cell abundance (two-sided Kolmogorov-Smirnov test). **B.** Classification results in terms of Area Under the Precision Recall Curve using information from all clusters. The shaded region represents the standard deviation of 10 repetitions of the classification routine. Horizontal dashed line represents the baseline precision. **C.** Classification results in terms of Area Under the Precision Recall Curve using information from clusters with significant differences in cells per cluster (shown in color in the minimum spanning tree). **D.** Classification results in terms of Area Under the Precision Recall Curve using information from all clusters, for a new FlowSOM clustering with 400 clusters. **E.** Classification results in terms of Area Under the Precision Recall Curve using information from clusters with significant differences in cells per cluster (shown in color in the minimum spanning tree). **D.** Classification Recall Curve using information from clusters, for a new FlowSOM clustering with 400 clusters. **E.** Classification results in terms of Area Under the Precision Recall Curve using information from clusters with significant differences in cells per cluster (shown in color in the minimum spanning tree), for the new FlowSOM clustering with 400 clusters.

every patient, and the results are shown in Figure 3A. Only one cluster (cluster 32 in
 metacluster 1) exhibited statistical significance (p<0.05), as determined by a
 two-sided Kolmogorov-Smirnov test.

¹⁹⁴ This, however, was insufficient to conclude the lack of predictive power of the

number of cells per cluster. Indeed, although each cluster individually did not present 195 clear differences, non-linear interactions between all clusters could create a region in 196 which relapse patients are more clearly distinguished. We tested this by building a 197 classifier for relapse prediction that uses cells per cluster as input. We implemented a 198 nested cross-validation scheme and included four supervised machine learning 199 algorithms: Naive Bayes, Random Forest, K-Nearest-Neighbors and linear Support 200 Vector Machine. For robustness, we repeated the classification 10 times. More 201 details about the classification routine can be consulted in the 'Methods' section. The 202 average Precision-Recall curve obtained is shown in Figure 3B. We used the Area 203 Under the Precision-Recall Curve (AUCPR) to summarize the result. This is 204 equivalent to the average precision of the classifier and can be interpreted as the 205 probability that a predicted relapse is a true relapse. Its value was close to the 206 baseline precision, which is the proportion of relapse patients in our dataset (0.202, 207 Table 1). This means that the features used for classification had no prognostic value. 208 We repeated the classification but using only the cluster in which significant 209 differences were found (Figure 3C). We obtained a higher precision compared to 210 using all information, although still close to the baseline classifier. To explore the 211 possibility of finding more relevant prognostic information, we repeated the clustering 212 with 400 FlowSOM clusters. When using all clusters, the classification results were 213 almost identical to the 50 cluster case (Figure 3D). We finally repeated the 214 classification using only the significant clusters (Figure 3E). This scenario reported 215 the highest performance, but still far from a significant enhancement compared to the 216 baseline classifier. We finally assessed the reliability of these results by performing 217 stability and overfitting checks (Figure S5). 218

Relative marker expression is similar between relapse and non-relapse patients across cell subpopulations

Following the assessment of the prognostic significance of cell abundance, we turned 221 to marker expression within each cell subpopulation. The distributions depicted in 222 Figure 4A portray the aggregated marker expression for relapse and non-relapse 223 patients within each metacluster. The patient-specific distributions that contribute to 224 these aggregated distributions are shown in Figure S6. Most markers across the 225 majority of metaclusters did not exhibit noteworthy disparities between the relapse 226 and non-relapse groups. The exceptions are metacluster 4, which showed 227 underexression of CD10 and overexpression of CD20 in relapse patients, as well as 228 more general differences in markers CD38, CD45 and CD58; and metacluster 6, 229 which displayed differences in CD10 and CD34. These metaclusters are associated 230 with minor subpopulations and part of the leukemic clone respectively. It remained to 231 be seen that the significance of these disparities were reproducible at an 232 individual-patient level, rather than being confined to the population level. Following 233 the rationale of the previous section, we aimed to test whether individual patients' 234 marker expression could predict relapse. 235

To address this, we summarized the marker expression distributions of each

9

patient within every metacluster using the median and the first four statistical 237 moments: Mean, standard deviation, skewness and kurtosis (Statistical moments of 238 order 1 to 4). This procedure produced five distinct datasets, each corresponding to a 239 specific metric, where each row encapsulated a patient's marker distribution 240 summary. Additionally, we constructed a combined dataset with all features to 241 explore whether a combination of metrics would yield more informative results. 242 Furthermore, we created a final dataset comprising exclusively those features 243 displaying statistically significant differences, as done in the previous section 244 (Kolmogorov Smirnov test, α = 0.05). We used the classification routine to check the 245



Figure 4. Expression-based classification. A. Aggregated marker expression of relapse and nonrelapse patients per metacluster. **B.** Classification results in terms of AUCPR. Black dashed line represents baseline precision. Color denotes metacluster. Circles represents the average precision obtained when using all the distribution metrics together to train the classifier. Asterisk represents the same average precision when using only those features with significant differences according to a Kolmogorov-Smirnov statistical test ($\alpha = 0.05$). **C.** Classification results in terms of AUCPR for a subset of patients (N=158) with an increased number of markers. **D.** Classification results in terms of AUCPR for a higher resolution clustering (400 FlowSOM clusters, 20 metaclusters).

predictive power of each dataset. A summary of the workflow followed in this section 246 is shown in Figure S7. The results are shown in Figure 4B. For each metacluster, we 247 show the average precision (equivalent to AUCPR) obtained by using all the 248 information versus only the features with significant differences, as done in the 249 previous section with cell abundance. We also show the same information for the full 250 cohort, without segregating by metaclusters. The results for individual metrics 251 (median, mean, standard deviation, skewness and kurtosis) are shown in Figure S8. 252 The conclusion is straightforward: the information contained in marker expression 253 distribution lacks predictive capacity, given that the majority of AUCPRs marginally 254 exceeded the baseline precision. The best result was a precision of 42% when using 255 only the significant features in metacluster 5, which correspond to myeloid cells. 256 Notably, the leukemic clone metaclusters (1, 2 and 6) contained no prognostic 257 information. 258

We explored the possibility that the observed outcome could stem from an 259 insufficiency of detail in the information under examination for each patient. То 260 address this, we repeated the analysis incorporating two alterations. Firstly, we 261 expanded the set of markers selected for analysis. However, this came at a cost: the 262 patient count diminished from 188 to 158. Employing the same clusters identified in 263 the original analysis, we searched for differences within the new markers (IgM, 264 cyTDT, cyMPO, cyCD3, CD13, CD22, CD3, CD33), but the improvement in the 265 predictive power of the routine was negligible: we obtained an increment of 5% of 266 precision on average (Figure 4C). In subsequent investigation, we studied whether 267 the challenge laid not in marker quantity but rather in the size of the clusters. Using 268 the initial set of 8 markers, we reconsidered the 400-cluster outcome from the 269 previous section, which resulted in 20 metaclusters. Two of the metaclusters (3 and 270 19) lacked enough patients to reliably estimate performance. For the remaining 271 metaclusters, the improvement was also unremarkable, especially in clusters 272 associated with the leukemic clone (red and blue colors) (Figure 4D). The best result 273 was an average precision of 50%, slightly superior than the best precision in the 274 default analysis but in a different subpopulation. The reliability of this set of results 275 was also assessed as in the previous section by calculating the stability of the 276 classifier (Figure S8). 277

To conclude, we performed two additional analyses. We first considered whether 278 the preprocessing of the data could be responsible for the lack of predictive 279 To explore this, we replicated the analysis using the cyCombine information. 280 algorithm for file matching (see 'Methods'), and our findings concurred with the 281 conclusions detailed earlier (Figure S9). Lastly, we considered only those patients 282 which were initially diagnosed as intermediate risk, to check if the more intensive 283 treatment received by high risk patients could bias the results. This resulted in a 284 reduced cohort of 119 patients. The results were also similar to the above (Figure 285 S10). Hence, irrespective of treatment received, preprocessing technique employed, 286 number of markers considered, cluster size and distribution metric, marker 287 expression of FC data at diagnosis failed to predict relapse. 288

11

Biomarker discovery algorithms from the literature support the findings of themain analysis

We contrasted our findings with other algorithms from the literature designed for 291 biomarker discovery and outcome prediction. A description of their functionality and 292 implementation can be found in the 'Methods' section. The results for each of them 293 are shown in Figure 5. The first example is Cydar²⁹, which is designed for differential 294 The clusters (hyperspheres in Cydar terminology) with a abundance discovery. 295 sufficient number of cells are projected onto the UMAP embedding employed in the 296 previous sections (Figure 2). Those hyperspheres with significant differences in 297 abundance (according to a lasso-regularized logistic regression) are plotted with 298 wider radius and colored according to the fold change in abundance between both 299 group of patients (Figure 5A). To check the predictive power of such hyperspheres, 300 we extracted the number of cells per patient and hypersphere and ran the 301 classification routine previously described, with results similar to the best models in 302 the previous section (Figure 5B). The difference here is that due to the lower size of 303 the clusters (hyperspheres), there are less patients per cluster (Figure 5C), which 304 makes the results less generalizable. The second example is Citrus³⁰. The results for 305 both abundance and median expression (Figure 5D) indicate the lack of predictive 306 information, regardless of regularization threshold. In both cases the null classifier 307 (no features, leftmost regularization threshold) was the best classifier, with an error of 308 20.2%. This number is the proportion of relapse patients in our dataset, which means 309 the algorithm was classifying all patients as non-relapse. Further, the False Discovery 310 Rate shows all the characteristics of a classifier unable to discriminate³¹. The Citrus 311 algorithm also reports the clusters with potential predictive capacity (Figure S11A-B). 312 The third example is cellCNN³², which uses a convolutional neural network. We 313 complemented it with a nested loop that allowed us to provide two conclusions: First, 314 the lack of a inner validation routine makes the algorithm more prone to overfitting, as 315 we see in the comparison between the accuracies of the inner and outer loops 316 (Figure 5E). Second, the performance in terms of AUCPR did not improve previous 317 tests (Figure 5F). This algorithm also reports the characteristics of the most 318 significant cells, which are included in Figure S11C-D. Finally, we tested Diffcyt²⁶ on 319 the metaclusters that were already obtained by FlowSOM (Figure 2). This algorithm 320 showed no significant differences in cell abundance per metacluster (Figure 5G) but it 321 did detect significant differences in expression (Figure 5H). On closer inspection, we 322 noticed that those significant features were the ones that displayed differences in 323 aggregated marker expression (Figure 4A). We already showed how this sum of 324 distributions does not necessarily entail that individual patients follow the same trend 325 (see Figure S7) and that a classifier could still be unable to properly predict relapse, 326 as shown in Figures 4B-C. 327

The conclusion of this section is that other algorithms that aim for the same goal as this study and follow a comparable methodology are also unable to detect differences between relapse and non-relapse patients. This applies to analyses centered on both cell abundance and marker expression.



Figure 5. Results from other biomarker discovery algorithms. A. Cydar hyperspheres (black) projected on UMAP embedding from Figure 2C (gray). Significant hyperspheres are colored according to fold change in abundance. B. Classification results from the cell abundance of the significant hyperspheres. Interpretation is as in Figure 3B-E. C. Number of patients in significant cydar hyperspheres split in relapse (R) and non-relapse (NR). Top row displays the reference of 188 patients (38 relapses). D. Citrus results for median expression (left) and abundance (right). Represented are cross-validation error rate (Red) and false discovery rate (blue). Green dot represents the error rate of the best model according to the minimum cross-validation error rate. Orange rhomboid represents the error rate of the best model according to the one standard deviation criterion. Yellow triangle represents the best model according to the lowest compatible false discovery rate. E. Comparison between the accuracy in the outer and inner loops of the CellCNN algorithm. F. AUCPR curve in the outer loop of the CellCNN algorithm. G. Diffcyt differential abundance test. Each row contains the individual patient cell percentage in a metacluster (1 to 8). The algorithm includes the fold change between status (relapse R in red vs non-relapse NR in blue) and the statistical significance of the results (gray vs green) H. Diffcyt differential expression test. Row annotation includes the marker and the metacluster in which significant differences were found.

332 **DISCUSSION**

Approximately 15% of children diagnosed with BCP-ALL will suffer relapse or 333 refractory disease, and the prognosis for this subgroup is significantly worsened. 334 Despite advancements in therapy through refined chemotherapy regimens, the 335 potential for further therapeutic success appears rooted in alternative treatments or 336 more precise risk assessment upon diagnosis. This underscores the importance of 337 enhancing our capability to anticipate disease progression at the individual patient 338 level. In this investigation, we have compiled an extensive FC database for childhood 339 BCP-ALL. A total of 252 patients from three hospitals participated in the study, with 340 188 patients advancing to the computational analysis phase. The objective of the 341 study was to examine whether patients experiencing relapse exhibit distinctive 342 patterns within their FC data at diagnosis. In other words, the goal was to test if FC 343 data at diagnosis has prognostic value with regards to long-term response. 344

To fulfill this objective, we preprocessed and normalized the data and we carried 345 out a file merging step in order to integrate the different aliquots of each patient into a 346 single file, after comparing the performance of different imputation methods. We 347 concluded that direct nearest neighbor imputation was the most 348 distribution-preserving algorithm. We hypothesize, however, that this may be only 349 applicable to the kind of data considered in this study (in terms of markers included 350 and type of distributions). This is clearer after noting the differences with the 351 conclusions reached in a recent review on imputation methods²¹. Without being 352 exhaustive, the presence of a dense and homogeneous clone could make the data 353 more suitable for merging algorithms of one kind, whereas more balanced or 354 heterogeneous bone marrow distributions would benefit from other algorithms. The 355 preprocessing step, the normalization, and the previous clustering step can also 356 impact the values and range of the metrics employed to measure distribution 357 differences. We therefore recommend repeating this assessment when dealing with a 358 different disease or high-dimensional data of other kind. 359

The selected patients were then pooled together and clustered with FlowSOM. We 360 visually examined the data structure through its UMAP embedding, revealing minimal 361 disparities between relapse and non-relapse patients. We extracted cell abundance 362 per patient at the cluster level and summarized marker expression at the metacluster 363 level by means of the first four statistical moments of the expression distribution: Mean, 364 standard deviation, skewness, and kurtosis. We also computed the median of the 365 distribution, a classical FC metric. All these features were input into a nested cross-366 validation scheme, which aimed to identify the optimal classifier for each dataset and 367 assess its performance on unseen data. The performance of such classifiers served 368 as an indicator of the prognostic value of the dataset. 369

The outcome of the primary analysis directly contradicts the initial hypothesis: FC data obtained at diagnosis does not appear to harbor information relevant to the prediction of relapse. Cell abundance per cluster is unable to predict relapse, even when increasing the number of clusters and when using only the ones with significant

differences between relapse and non-relapse groups. Likewise, no distribution metric 374 is able to significantly improve the baseline precision. Considering all metrics together 375 in a single dataset or retaining only the ones with significant differences also failed to 376 improve outcomes. We further increased the number of clusters and the number of 377 markers, the latter with a reduction in the number of patients from 188 to 158, and we 378 also repeated the analysis considering a different file merging algorithm, to test the 379 possibility that the preprocessing routine masked differences in abundance or 380 expression. Finally, we restricted the analysis to intermediate risk patients, to account 381 for the possible confounding effect of the more intensive treatment received by high 382 risk patients. The conclusion remained unaltered across all these studies. The most 383 precise classifier was found when increasing the number of clusters and using only 384 the metrics with significant differences between groups. This classifier achieved an 385 average precision of 0.507. This indicates that, within this particular classifier, the 386 likelihood of a predicted relapse corresponding to an actual relapse stands at 50.7%. 387

The pipeline followed in this study was designed to encompass and extend 388 previously published algorithms by offering a more comprehensive characterization of 389 marker expression distributions and employing non-linear classifiers with a more 390 rigorous resampling scheme. Despite these advancements, we verified the outcomes 391 against other open-source algorithms. We specifically assessed Cydar²⁹, Citrus³⁰, 392 Diffcyt²⁶, and CellCNN³², which are among the most frequently referenced algorithms 393 for discovery analysis in FC. Cydar, Citrus, and Diffcyt incorporate tests for differential 394 Cydar identified several clusters exhibiting significant differences in abundance. 395 abundance, with a performance akin to the classifiers obtained in the primary 396 analysis. As a drawback, those clusters only contained a subset of the full cohort of 397 patients. Citrus and Diffcyt failed to identify differences bearing prognostic value. 398 These two algorithms additionally include tests for differential expression. Citrus 399 identified three features, but the classifier's performance proved inferior to the null 400 model. In the case of Diffcyt, the identified features held significance at a population 401 level but struggled to consistently discern individual patients. Finally, the outcomes 402 from cellCNN mirrored those of the other classifiers, with performance marginally 403 surpassing the baseline classifier. The aforementioned findings further underscore 404 the established conclusion that the metrics used to characterize the distributions of 405 surface markers fail to differentiate between patients who experience relapse and 406 those who do not. 407

The initial hypothesis of this study rested on the premise that the leukemic clone in 408 relapsing patients differs from that of successfully treated individuals, and that such 409 distinctions manifest in the immunophenotype and could then be captured through FC 410 measurements. The negative outcome we have obtained in this study offers room for 411 diverse interpretations. It is possible that the immunophenotype of relapsing patients 412 does not exhibit distinctive characteristics. While genetic differences are known to 413 play a fundamental role in the origin and potentially the relapse of leukemia^{33,34}, these 414 differences may not necessarily translate to variations in marker expression 415 distributions. Rather, they may only be found through genomics, transcriptomics or 416

In this line, recent research has demonstrated the feasibility of metabolomics. 417 predicting relapse in infants with MLL-rearranged ALL by single-cell transcriptomics³⁵. 418 It remains essential to conduct further investigations to ascertain the predictive 419 potential of a comprehensive panel of mutations for the broader population. 420 Alternatively, immunophenotypic disparities might emerge post-therapy. Such a 421 scenario could be attributed to chemotherapy-induced bottleneck selection, which has 422 been shown to impact the phenotype more significantly than genotype³⁶. This could 423 be probed by revisiting this study with FC data from a later time point, although this 424 approach would deviate from the initial goal of refining risk stratification at diagnosis. 425

With respect to the conditions of this study, it is also feasible that 426 immunophenotypic distinctions exist but are only discernible within small cell 427 subpopulations. Such differences might elude detection even with high-resolution 428 clustering if the number of cells per patient is not increased. This hypothesis could be 429 explored by imposing stricter limitations on the number of cells per patient, although 430 this would inevitably reduce the total number of patients in the study. Another 431 potential consideration is that immunophenotypic disparities manifest in markers 432 beyond the ones routinely assessed in clinical practice. Evaluating this notion would 433 require prospective studies. Finally, it can be the case that immunophenotypic 434 disparities exist but are obscured by the extensive preprocessing and normalization 435 required to integrate data from multiple centers. No immediate alternative exists until 436 the clinical adoption of next-generation cytometers that can measure a larger number 437 of markers simultaneously and are more amenable to standardization. 438

Despite the scope and scale of this study, as well as the evidence gathered in 439 support of the negative conclusion, there are still alternative ways of exploring the 440 potential prognostic value of FC, a line of research that is still relatively unexplored for 441 this particular disease. Indeed, a number of works employ machine learning 442 techniques to answer questions relative to BCP-ALL, but applications for relapse 443 prediction from FC data at diagnosis are still uncommon. For instance, Pan et al.³⁷ 444 utilized clinical data from a cohort of 336 patients to predict relapse. However, this 445 study lacked FC data and incorporated response variables (such as MRD at days 15 446 and 33), thereby limiting its applicability to the diagnosis phase. A similar predictive 447 framework based on clinical features was presented by Mahmood et al.³⁸. Moving 448 closer to the objectives of the present study, Good et al.¹⁵ gathered mass cytometry 449 data at diagnosis to achieve a relapse prediction AUC of 0.85 using an elastic net 450 model. However, their database only encompassed 54 patients, and the validation 451 was confined to a single train-validation split, thereby hampering direct comparability 452 with our results. Similar constraints apply to an earlier work by our own group that 453 included 56 patients to identify differences in expression¹⁶. Finally, we recently 454 published a framework that uses topological data analysis for feature extraction and 455 includes a classifier that reached high accuracy and AUC with an increased number 456 of patients $(N = 96)^{17}$. This study meets the criterion of moving beyond the 457 conventional feature engineering in FC and the preliminary results encourage the 458 search for differences in immunophenotype of relapsing patients by means of more 459

460 complex methods.

To sum up, we have performed a machine learning-based relapse classification 461 study involving 252 patients diagnosed with childhood BCP-ALL. A detailed 462 characterization of immunophenotype and different cluster resolutions have been 463 unable to distinguish relapse from non-relapse patients, and other algorithms from the 464 literature exhibited similar outcomes. We conclude that different characterizations of 465 FC data are required to uncover its potential prognostic value, pending the availability 466 of high-dimensional omics data at diagnosis and more advanced cytometers that 467 circumvent some of the challenges found throughout our study. 468

469 **METHODS**

470 Study population

252 patients and three different spanish hospitals participated in this study. We 471 collected data from 116 patients from Hospital Niño Jesús, Madrid (HNJ), diagnosed 472 between January 2013 and January 2022; 80 patients from Hospital Virgen de la 473 Arrixaca, Murcia (HVA), diagnosed between May 2011 and July 2022; and 56 patients 474 from Hospital Virgen del Rocío, Sevilla (HVR), diagnosed between January 2012 and 475 207 patients had long-term remission and 44 patients relapsed. All July 2021. 476 patients are in the age range 0-19. We dropped those which continued treatment at 477 another institution or that had not reached 1 year of follow up, with 211 patients finally 478 proceeding to the main analysis (Figure S1). The data collected included FC files 479 from bone marrow samples at diagnosis and additional clinical information: Age, sex, 480 phenotype, risk group, CNS involvement, absolute lymphocyte count (ALC), 481 genetic information immunophenotype and (karyotype and chromosomal 482 translocations). Informed consent was obtained from the parents or legal guardians 483 according to the Helsinki Declaration. 484

485 **Treatment**

Treatment was administered according to the Spanish National protocols 486 SEHOP-PETHEMA 2013 and INTERFANT-06 in patients under 1 year old. Older 487 patients from HVR and HVA followed the previous consecutive versions of this 488 protocol (LAL/SEHOP 01 for low risk patients, LAL/SEHOP 96 for intermediate risk 489 patients and LAL/SHOP 05 for high risk patients). These protocols are based on the 490 Berlin-Frankfurt-Munster (BFM) backbone and consists of a four-drug induction 491 phase (IA), followed by induction IB, consolidation, reinduction, and maintenance. 492 High risk patients receive three specific high-risk blocks, three reinduction cycles, and 493 maintenance. The total duration of therapy is 2 years. 494

495 **Risk stratification**

⁴⁹⁶ Risk stratification criteria is based on age, lymphocyte count at diagnosis, ⁴⁹⁷ extramedullary infiltration, cytogenetics and early response to treatment.

SEHOP-PETHEMA 2013 assigns a low risk to patients who meet the following
criteria: Age between 1 and 10 years, ALC less than 20 · 10⁹ cells/liter at diagnosis,
absence of CNS or testicular infiltration, high hyperdiploidy or presence of t(12;21),
absence of t(1;19), no MLL rearrangement, good early response and good response
to prednisone. High risk patients verify at least one of the following: presence of
t(4;11), hypodiploidy, BCR-ABL rearrangement or poor early and prednisone
response. Patients who do not meet either criteria are assigned to intermediate risk³⁹.

505 **Patient outcome**

Patients are assigned to either relapse or non-relapse group. Bone marrow relapse is diagnosed with the same criteria as the initial diagnosis: presence of >25% of leukemic blasts in bone marrow. Extramedullary relapses require a biopsy of the tissue or a sample of cerebrospinal fluid for confirmation. For a patient to be included in the nonrelapse group we require at least one year of disease-free survival after treatment.

511 Flow cytometry data

All data is retrospective. Bone marrow samples have been handled following standard clinical procedures (there is no specific design for this study). Monoclonal fluorochrome-conjugated antibody combinations employed at each hospital are shown in Tables S3-S5. Some patients presented variations from this standard (marker changes, additions or omissions).

517 **Preprocessing of flow cytometry data**

⁵¹⁸ Preprocessing encompassed a manual and a computational step. The manual step ⁵¹⁹ consisted in checking each aliquot for acquisition errors and removing doublets and ⁵²⁰ debris (Fig. S2A). At this step we required that all aliquots contain CD19 and CD45 ⁵²¹ markers. For this reason, certain patients (mostly those diagnosed at earlier dates) ⁵²² were excluded from the study (1 from HVA and 7 from HVR). Aliquots with too little ⁵²³ cells of with strong batch effects were also removed.

The compensated files were subsequently exported to undergo the computational 524 preprocessing step⁴⁰. This preprocessing involved transforming data with the 525 standard Logicle transform, removing margin events (this is done more efficiently 526 here than manually) and renaming the channels to uniformize marker names across 527 patients. Finally, each marker was normalized to the [0,1] interval by means of a 528 modified max-min transformation: Instead of taking the maximum and minimum 529 values, we took the 99th and 1st quantile respectively, making the normalization more 530 robust to outliers. This transformation implies that we are comparing relative 531 expression of a marker instead of the absolute expression. 532

Finally, we had to consider the issue of backbone markers displaying inter-aliquot differences. Some causes of this variability are staining problems, acquisition errors and other batch effects. To account for this source of heterogeneity we first sampled 10000 cells from each tube and then performed quantile normalization, a technique

⁵³⁷ already used in RNA-seq data to make distributions more similar. Instead of ⁵³⁸ normalizing the whole distribution we followed the approach in the cytoNorm ⁵³⁹ algorithm⁴¹: we performed flowSOM clustering with 5 clusters and then normalized on ⁵⁴⁰ a per cluster basis (Figure S2B).

541 File merging

File merging (also file matching, panel merging or imputation) refers to the process of 542 combining all the information from a FC experiment into a single file. The issue arises 543 from the fact that flow cytometers can measure a limited number of colors, i.e. the 544 expression of a limited number of protein cell markers. To obtain information for more 545 markers, the sample is divided in several tubes or aliquots and each tube measures a 546 different set of proteins, while maintaining a subset of them constant (backbone 547 markers). This is enough for manual inspection of the sample but for data analysis 548 the combined file allows for a much deeper analysis. Figure S2C illustrates the 549 starting point and endpoint of this part of the analysis. 550

Several methods have already been developed for this purpose. Most of them rely 551 on nearest neighbor imputation: Backbone markers are used to find the closest 552 neighbors (cells with the highest surface protein similarity), and the missing 553 information is copied from the respective neighbor. This was first published by 554 Pedreira et. al.²². Later works use slightly modified versions that aim to correct 555 cytoBackBone²³ includes the concept of acceptable and artifacts and biases: 556 non-ambiguous nearest neighbors (data is only imputed if a cell's closest neighbor is 557 also the other cell's closest neighbor) and CYTOFmerge²⁴ used median expression 558 from the closest 50 neighbors instead of the single closest one. A more recent 559 method (cyCombine)²⁵ follows a different methodology: It finds clusters in the space 560 of backbone markers and then approximates the distribution of the remaining markers 561 using kernel density estimation. The missing information is then imputed using 562 probability draws. This is similar to other approach by Lee et. al.⁴², which requires 563 domain knowledge but demonstrated that pre-matching clustering enhances 564 performance and reduces the risk of spurious cell populations appearing in the data. 565 These previous steps improve quality of merging in terms of preserving the original 566 distribution at the expense of removing cells that are too exclusive of one file and that 567 would otherwise impute noise. 568

In light of these advances, the question arises as to which one is the most suitable 569 method for conducting downstream analysis on a patient dataset. A recent 570 comprehensive review delved into this question²¹, using an array of metrics to 571 compare the performance of the different algorithms. They concluded that there is not 572 a clear winner and caution needs to be taken when performing downstream analysis 573 with imputed data. A similar approach was carried out by Perdersen et. al.²⁵ when 574 demonstrating the cyCombine functionality. The Earth's Mover Distance (EMD) was 575 employed to compare the distribution of a marker in the original tube versus the 576 This distance, also known as Wasserstein distance, measures the merged file. 577 minimum cost required to transform one distribution into another. In the context of 578

flow cytometry, this cost is associated with moving cells from one marker expression state to another. Lower EMD values indicate a closer match between the original and imputed distributions, suggesting a more accurate imputation process. Its suitability for comparing marker expression distributions in the context of flow cytometry was recently demonstrated²⁰.

Here, we preprocessed patients from each hospital as described above and 584 imputed the missing values according to the four methods mentioned in the main text: 585 Direct nearest-neighbor imputation (basic), CYTOFmerge, cytoBackBone and 586 cvCombine. For the backbone markers (CD19, CD34 and CD45), since these 587 markers are present in all aliquots, we measured the difference of expression in each 588 aliquot with the expression in the merged file and computed the average to get an 589 upper bound for acceptable inter-aliguot differences. For the remaining markers we 590 computed the EMD between the expression in the merged file and the expression in 591 the specific aliquot in which they were present. Other metrics that were used to 592 assess the performance of the different algorithms were the ratio between cells to 593 merge and final number of cells (some of the algorithms discard cells) and the 594 computation time. 595

596 Patient selection

The selection of patients and markers that proceeded to the final study was 597 conducted post-normalization and merging. This is due to the fact that certain 598 aliquots were excluded during these steps, resulting in a variation in the markers 599 available for each patient compared to the preprocessing phase. We first reduced 600 each patient (i.e. each merged file) to 10000 cells, removing patients that did not 601 reach this amount. There exists a tradeoff between the number of markers analyzed 602 and the number of patients. For the main analysis, 10 markers were retained (FSC.A, 603 SSC.A, CD19, CD10, CD20, CD34, CD66, CD58, CD45, CD38) for a total of 188 604 patients (95 from HNJ, 46 from HVR and 47 from HVA). 605

606 Flow cytometry visualization

FlowSOM was run with parameters x = 5, y = 10 and maxK = 20. We consistently obtained an optimal number of 8 metaclusters. For UMAP, we subset 1000 cells from each patient and pool the subset files to obtain the embedding of the bone marrow of all patients. After a visual exploration, we selected UMAP hyperparameters min_dist = 0.1, n neighbors = 50 and the rest with default values (Figure S12).

612 **Feature extraction**

The most common features for analyzing flow and mass cytometry data are abundance (relative or absolute) and expression, measured as the median intensity of a marker (MFI), in general or on a per-cluster basis. This has been the case in most of the studies and methods used for biomarker discovery in FC data applied to leukemia (Table S5). However, a single number might not be enough to characterize

the full marker distribution and thus to discover differences in expression, intensity 618 and immunophenotype. Here, we computed for each cluster not only the abundance 619 and median expression but also the first four moments of the distribution (mean, 620 standard deviation, skewedness, and kurtosis). We created a dataset for each 621 feature and a dataset with all features together, in order to find which characterization 622 is best for detecting differences in expression and to see if the combination of all 623 enhances the predictive capacity. We finally created a dataset with only those 624 features that present significant differences between relapse and non-relapse 625 patients according to a two-tailed Kolmogorov-Smirnov test. 626

627 Classification

Most of the published methods for analyzing FC data (Table S5) use linear models to 628 perform moderated tests in order to find significant differences in expression (median 629 intensity). The exception are neural network based algorithms, which do not explicitly 630 perform feature selection but include the FC file as input for the algorithm. The 631 differential expression methodology is standard in transcriptomics analysis, when 632 looking for genes that are overexpressed under given conditions⁴³. For the problem 633 and the hypothesis of this study, finding a significantly over- or under-expressed 634 marker might not be enough to distinguish a relapse from a non-relapse patient. In 635 other words, while we would be able to make a statement of the kind "relapse patients 636 on average have a higher expression of marker X", we would not be able to say 637 whether a new patient belongs in the relapse or non-relapse group. Further, these 638 analyses consider markers individually, but it could be the case that, while there 639 might not be significant differences in MFI of a marker, we could find a region in the 640 space of MFIs that separates both groups of patients. 641

Without any previous knowledge about the characteristics of this region and given 642 that it can be quite different depending on which metric we are considering, we could 643 not say a priori which classification model was best for this task, nor which 644 hyperparameters of such model were optimal. For this reason, the classification 645 routine had to include some form of internal validation to make this decision based on 646 We did this by means of nested cross-validation^{44,45}. This approach the data. 647 consists of two cross-validation loops, an outer loop and an inner loop. The inner loop 648 is used to find the best model and its hyperparameters, and the outer loop is used to 649 get an estimate of performance in unseen data. For the inner loop we performed 650 9-fold cross-validation repeated 20 times to get a more robust estimate, and for the 651 outer loop we performed 5-fold cross-validation, repeated 10 times. This resampling 652 scheme implied that each inner fold contained 16 patients on average, with 2 of them 653 belonging to the relapse group. 654

We chose 4 models that are widely used and ensure that different types of boundaries are explored: K-Nearest Neighbors, Naïve Bayes Classifier, Random Forest, and Linear Support Vector Machine. Each time we trained a model we use random grid search to select the optimal hyperparameters (Table S6). The best model was selected based on the one standard deviation rule using the AUCPR

⁶⁶⁰ curve, which is more suitable for problems with unbalanced data⁴⁶. Hyperparameter ⁶⁶¹ estimation and model selection were thus performed together⁴⁷.

For every dataset, the nested cross-validation routine produces 50 performance 662 estimates (AUC-PR) and identifies 50 'best models' (obtained from the 10 repetitions 663 of 5-fold cross-validation in the outer loop). We summarized the 50 AUC-PR values by 664 calculating their average, and the 50 best models by using a measure of heterogeneity 665 as a surrogate of the stability of the routine. This stability measure is assigned a value of 666 1 if the same model is consistently selected in all outer folds, and 0 if the four models are 667 equally frequent. It is important to note that while this measure can indicate instability 668 or unsuccessful optimization, it is possible for two models to perform nearly equally 669 well in identifying the best boundary, making them equally suitable for the task at hand. 670 Thus, it's essential to consider the degree by which the top model has been selected 671 and its associated level of performance. 672

To sum up, for each dataset we had a measure of the predictive information it contains (average AUCPR) and a proxy of the reliability of this measure (stability index). These two metrics were employed in conjunction to assess the predictive information across different metrics and metaclusters. Figure S7 provides an overview of the feature extraction and classification steps.

678 Comparison with other algorithms

We already mentioned the existence of other algorithms and studies that aim to 679 predict a clinical outcome from flow cytometry data (table S5). The way they are 680 designed follows a similar pattern: All of them begin from a set of flow cytometry files 681 (one per patient) and cells are clustered with a different algorithm depending on the 682 method. Each cluster is summarized by means of the abundance and the median 683 fluorescence intensity of a marker, and these are in turn used for classification. 684 Generalized linear models are the usual choice, as many algorithms are inspired by 685 RNA or DNA microarray data analysis. The exception to this two-step process are 686 neural networks based algorithms, since feature extraction is performed in the inner 687 layers of the network. The pipeline that we followed here aimed to generalize this 688 'classical' approach by going beyond the typical characterization of a marker 689 distribution (MFI) and by including a broader and more thorough classification routine. 690 To validate the conclusions of this study, we selected four of the most cited algorithms 691 and compared the results. Below we summarize the characteristics and functionality 692 of the selected algorithms. 693

 Cydar²⁹ identifies differentially abundant cell populations between groups. It was 694 originally proposed for mass cytometry data but can be extended to any 695 It clusters cells into hyperspheres, extracts cell multidimensional dataset. 696 abundance and tests for significant differences by means of a negative binomial 697 generalized linear model, controlling for the spatial false discovery rate. In this 698 study we subsampled 1000 cells from each patient, clustered with scaling factor 699 0.2, removed hyperspheres with average counts below 5 and applied the QL 700 framework to test for significant differences. After correcting for multiple testing 701

(spatial FDR<0.05), relevant hyperspheres and the respective fold changes in
 abundance were visualized on the UMAP embedding of the dataset.

Citrus³⁰ identifies cell subpopulations associated with a clinical or experimental outcome. It clusters cells in a hierarchical manner, extracts either abundance or median expression and uses regularized supervised learning algorithms to identify clusters of interest. For this method we also subsampled 1000 cells from each patient. We clustered with a minimum cluster size of 5% and 5 folds and tested with the nearest shrunken centroids algorithm (PAMR).

 CellCNN³² uses a convolutional neural network to detect rare cell subsets 710 associated with disease. As explained above, it bypasses an explicit feature 711 extraction process to go directly from the multicell inputs to the model prediction, 712 drawing inspiration from multiple instance learning. We ran the convolutional 713 neural network with 1000 cells, 1000 subsets, quantile normalization and scaling 714 already performed and the rest of parameters with the default values. The 715 default function performs hyperparameter tuning via a single train-test split. We 716 further included an outer loop (20 repeats of 5-fold cross-validation) to obtain an 717 unbiased estimate of performance, since a single train-test split would make the 718 estimation more prone to bias. 719

• Diffcyt²⁶ employs a combination of high-resolution clustering and empirical 720 Bayes moderated tests adapted from transcriptomics to perform differential 721 It is specifically intended for complex and/or flexible discovery analyses. 722 experimental designs. Like Citrus, each cluster is characterized by abundance 723 and median marker expression and these are modelled by statistical methods 724 based on the negative binomial distribution (Bayes estimation and generalized 725 linear models among others). We followed a previously published workflow to 726 run this framework⁴⁸. We reused the FlowSOM clustering obtained in the 727 visualization step of the study and used the edgeR method for differential 728 abundance testing and the limma method for differential expression testing. 729

730 Software

Manual preprocessing step was performed by means of FlowJo[™] v10.9 Software 731 The computational step was carried out in RStudio (BD Life Sciences). 732 (v2023.06.1+524, Posit team 2023) with the R Statistical Software (v4.2.2, R Core 733 Team 2022), using packages flowCore (v2.12.2, available at Bioconductor) and 734 flowWorkspace (v4.12.1, available at Bioconductor). File matching was also 735 performed in R adapting the code from packages cytoBackBone 736 (https://github.com/tchitchek-lab/CytoBackBone), cyCombine (v0.2.15, available at 737 https://github.com/biosurf/cyCombine) and CYTOFmerge 738 (https://github.com/tabdelaal/CyTOFmerge). Visualization made use of packages 739 Bioconductor) and uwot (v0.1.16, available at CRAN). FlowSOM (v2.8.0, 740 Classification was performed with caret (v6.0-94, CRAN) and rsample (v1.1.1, CRAN) 741 For the other algorithms of the literature, packages Cydar (v1.24.0, packages. 742

Bioconductor), Citrus (v0.0.8, available at https://github.com/nolanlab/citrus) and 743 Diffcvt (v1.20.0, **Bioconductor**) were run in R and cellCNN 744 (https://github.com/eiriniar/CellCnn) was run in Python v2.7 (Python Software 745 Foundation https://www.python.org/), all of them making use of the open source code 746 provided at their respective websites. 747

748 Hardware

The computational preprocessing, file merging, visualization and feature extraction routines were performed on a 3,4 GHz, 4-core, 16 GB memory iMac machine. The classification routine was run on a 3,2 GHz, 16-core, 96 GB memory Mac Pro machine. Runtime per dataset was 8-9 minutes (running each outer fold in a 31-core parallel cluster).

754 Data and code availability

The source code and functions used in this article can be consulted at https://github.c om/Almr95/Relapse-Prediction. This repository also includes the preprocessed and merged files of the 188 patients selected for the main analysis. The full database of anonymized FC files is available at http://flowrepository.org/id/FR-FCM-Z7A2.

759 SUPPLEMENTAL INFORMATION

⁷⁶⁰ Supplemental information can be found online at XXXX.

761 ACKNOWLEDGMENTS

This work was partially supported by project PDC2022-133520-100 funded by 762 Ministerio de Ciencia е Innovación/ Agencia Estatal de investigación 763 (doi:10.13039/501100011033) and European Union NextGenerationEU/PRTR; by 764 PID2022-140451OA-I00 funded Ministerio de Ciencia project bv 765 е Innovación/Agencia Estatal de investigación (doi:10.13039/501100011033) and 766 ERDF A way of making Europe; and by University of Castilla-La Mancha / ERDF, A 767 way of making Europe (Applied Research Projects) under grant 2022-GRIN-34405. 768 The support of Fundación Española para la Ciencia y la Tecnología (FECYT project 769 PR214), Asociación Pablo Ugarte (APU, Spain) and Junta de Andalucía (Spain) 770 group FQM-201 is also acknowledged. This work was also subsidized in its early 771 stages by a grant for the research and biomedical innovation in the health sciences 772 within the framework of the Integrated Territorial Initiative (ITI) for the province of 773 Cadiz (grant number ITI-0038-2019). 774

775 AUTHOR CONTRIBUTIONS

Conceptualization, V.M.P.G., M.R., and C.B.G.; Data curation, A.M.R., R.P.G., A.N.L., 776 S.C., J.F.R.G., E.G.V., T.C.V., Á.M.Q., A.C.R., M.R.O., M.V.M.S., A.M.P., J.L.F.S. and 777 C.B.G.; Formal analysis, A.M.R.; Funding acquisition, M.R. and V.M.P.G.; 778 Investigation, A.M.R., R.P.G., A.N.L. and S.C.; Methodology, A.M.R.; Project 779 administration, C.B.G., V.M.P.G. and M.R.; Resources, T.C.V., A.M.Q., A.C.R., 780 M.R.O., M.V.M.S., A.M.P., J.L.F.S. and C.B.G.; Software, A.M.R.; Supervision, 781 V.M.P.G. and M.R.; Writing—original draft, Á.M.R.; Writing—review & editing, Á.M.R., 782 R.P.G., A.N.L., S.C., J.F.R.G., E.G.V., T.C.V., Á.M.Q., A.C.R., M.R.O., M.V.M.S., 783 A.M.P., J.L.F.S., C.B.G., V.M.P.G. and M.R. All authors have read and agreed to the 784 published version of the manuscript. 785

786 **DECLARATION OF INTERESTS**

⁷⁸⁷ The authors declare no conflicts of interest.

788 **GENERATIVE AI USAGE**

During the preparation of this work, the authors used chatGPT (powered by OpenAl's language model, GPT-3.5; http://openai.com) in order to improve readability and language of the work. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.

793 **References**

- Pui, C.-H., Yang, J. J., Hunger, S. P., Pieters, R., Schrappe, M., Biondi, A., Vora, A., Baruchel, A.,
 Silverman, L. B., Schmiegelow, K., et al. (2015). Childhood acute lymphoblastic leukemia: Progress
 through collaboration. Journal of Clinical Oncology *33*, 2938. https://doi.org/10.1200/jco.2014.59.
 1636.
- Ceppi, F., Cazzaniga, G., Colombini, A., Biondi, A., and Conter, V. (2015). Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention. Expert Review of Hematology 8, 57–70. https://doi.org/10.1586/17474086.2015.978281.
- Schultz, K. R., Pullen, D. J., Sather, H. N., Shuster, J. J., Devidas, M., Borowitz, M. J., Carroll, A. J., Heerema, N. A., Rubnitz, J. E., Loh, M. L., et al. (2007). Risk-and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood *109*, 926– 935. https://doi.org/10.1182/blood-2006-01-024729.
- 4. Talleur, A. C., Pui, C.-H., and Karol, S. E. (2023). What Is Next in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. Lymphatics *1*, 34–44. https://doi.org/10.3390/lymphatics1010005.
- 5. Teachey, D. T. and Hunger, S. P. (2013). Predicting relapse risk in childhood acute lymphoblastic leukaemia. British Journal of Haematology *162*, 606–620. https://doi.org/10.1111/bjh.12442.

Basso, G., Veltroni, M., Valsecchi, M. G., Dworzak, M. N., Ratei, R., Silvestri, D., Benetello, A.,
 Buldini, B., Maglia, O., Masera, G., et al. (2009). Risk of relapse of childhood acute lymphoblastic
 leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
 Journal of Clinical Oncology 27, 5168–5174. https://doi.org/10.1200/jco.2008.20.8934.

- Dongen, J. J. van, Velden, V. H. van der, Brüggemann, M., and Orfao, A. (2015). Minimal residual
 disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized
 technologies. Blood, The Journal of the American Society of Hematology *125*, 3996–4009.
- 817 8. Pedreira, C. E., Costa, E. S., Lecrevisse, Q., van Dongen, J. J., and Orfao, A. (2013). Overview 818 of clinical flow cytometry data analysis: recent advances and future challenges. Trends in 819 Biotechnology *31*, 415–425. https://doi.org/10.1016/j.tibtech.2013.04.008.
- 820 9. Kalina, T., Flores-Montero, J., Van Der Velden, V., Martin-Ayuso, M., Böttcher, S., Ritgen, M.,
 821 Almeida, J., Lhermitte, L., Asnafi, V., Mendonça, A., et al. (2012). EuroFlow standardization of
 822 flow cytometer instrument settings and immunophenotyping protocols. Leukemia 26, 1986–2010.
 823 https://doi.org/10.1038/leu.2012.122.
- 10. Van Dongen, J., Lhermitte, L., Böttcher, S., Almeida, J., Van Der Velden, V., Flores-Montero, J., Rawstron, A., Asnafi, V., Lecrevisse, Q., Lucio, P., et al. (2012). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26, 1908–1975. https://doi.org/https://doi.org/10.1038/leu.2012.120.
- Duetz, C., Bachas, C., Westers, T. M., and van de Loosdrecht, A. A. (2020). Computational analysis
 of flow cytometry data in hematological malignancies: future clinical practice? Current Opinion in
 Oncology 32, 162–169. https://doi.org/10.1097/cco.000000000000607.
- Saeys, Y., Van Gassen, S., and Lambrecht, B. N. (2016). Computational flow cytometry: helping
 to make sense of high-dimensional immunology data. Nature Reviews Immunology *16*, 449. https:
 //doi.org/10.1038/nri.2016.56.
- Robinson, J. P., Rajwa, B., Patsekin, V., and Davisson, V. J. (2012). Computational analysis of high-throughput flow cytometry data. Expert Opinion on Drug Discovery 7, 679–693. https://doi. org/10.1517/17460441.2012.693475.
- Reiter, M., Diem, M., Schumich, A., Maurer-Granofszky, M., Karawajew, L., Rossi, G. J., Ratei, R.,
 Groeneveld-Krentz, S., and Sajaroff, O. E. (2019). Automated flow cytometric mrd assessment in
 childhood acute b- lymphoblastic leukemia using supervised machine learning. Cytometry Part A
 95, 966–975. https://doi.org/10.1002/cyto.a.23852.
- Good, Z., Sarno, J., Jager, A., Samusik, N., Aghaeepour, N., Simonds, E. F., White, L., Lacayo,
 N. J., Fantl, W. J., Fazio, G., et al. (2018). Single-cell developmental classification of b cell precursor
 acute lymphoblastic leukemia at diagnosis reveals predictors of relapse. Nature Medicine *24*, 474.
 https://doi.org/10.1038/nm.4505.
- 16. Chulián, S., Martínez-Rubio, Á., Pérez-García, V. M., Rosa, M., Blázquez Goñi, C., Rodríguez Gutiérrez, J. F., Hermosín-Ramos, L., Molinos Quintana, Á., Caballero-Velázquez, T., RamírezOrellana, M., et al. (2020). High-dimensional analysis of single-cell flow cytometry data predicts relapse in childhood acute lymphoblastic leukaemia. Cancers *13*, 17. https://doi.org/10.3390/
 cancers13010017.
- Chulián, S., Stolz, B. J., Martínez-Rubio, Á., Blázquez Goñi, C., Rodríguez Gutiérrez, J. F.,
 Caballero Velázquez, T., Molinos Quintana, Á., Ramírez Orellana, M., Castillo Robleda, A.,
 Fuster Soler, J. L., et al. (2023). The shape of cancer relapse: Topological data analysis predicts
 recurrence in paediatric acute lymphoblastic leukaemia. PLoS Computational Biology *19*,
 e1011329. https://doi.org/10.1371/journal.pcbi.1011329.

- Pui, C.-H., Yang, J. J., Bhakta, N., and Rodriguez-Galindo, C. (2018). Global efforts toward the cure
 of childhood acute lymphoblastic leukaemia. The Lancet Child & Adolescent Health 2, 440–454.
 https://doi.org/10.1016/s2352-4642(18)30066-x.
- Agarwal, M., Seth, R., and Chatterjee, T. (2021). Recent advances in molecular diagnosis and prognosis of childhood B cell lineage acute lymphoblastic leukemia (B-ALL). Indian Journal of Hematology and Blood Transfusion *37*, 10–20. https://doi.org/10.1007/s12288-020-01295-8.
- Orlova, D. Y., Zimmerman, N., Meehan, S., Meehan, C., Waters, J., Ghosn, E. E., Filatenkov, A.,
 Kolyagin, G. A., Gernez, Y., Tsuda, S., et al. (2016). Earth mover's distance (EMD): a true metric
 for comparing biomarker expression levels in cell populations. PLoS One *11*, e0151859. https:
 //doi.org/10.1371/journal.pone.0151859.
- Mocking, T., Duetz, C., van Kuijk, B., Westers, T., Cloos, J., and Bachas, C. (2023). Merging and
 imputation of flow cytometry data: a critical assessment. Cytometry Part A. https://doi.org/10.1002/
 cyto.a.24774.
- Pedreira, C. E., Costa, E. S., Barrena, S., Lecrevisse, Q., Almeida, J., van Dongen, J. J., and Orfao,
 A. (2008). Generation of flow cytometry data files with a potentially infinite number of dimensions.
 Cytometry Part A *73*, 834–846. https://doi.org/10.1002/cyto.a.20608.
- Leite Pereira, A., Lambotte, O., Le Grand, R., Cosma, A., and Tchitchek, N. (2019). CytoBackBone:
 an algorithm for merging of phenotypic information from different cytometric profiles. Bioinformatics
 35, 4187–4189. https://doi.org/10.1093/bioinformatics/btz212.
- Abdelaal, T., Höllt, T., van Unen, V., Lelieveldt, B. P., Koning, F., Reinders, M. J., and Mahfouz,
 A. (2019). CyTOFmerge: integrating mass cytometry data across multiple panels. Bioinformatics
 35, 4063–4071. https://doi.org/10.1093/bioinformatics/btz180.
- Pedersen, C. B., Dam, S. H., Barnkob, M. B., Leipold, M. D., Purroy, N., Rassenti, L. Z., Kipps, T. J.,
 Nguyen, J., Lederer, J. A., Gohil, S. H., et al. (2022). cyCombine allows for robust integration of
 single-cell cytometry datasets within and across technologies. Nature Communications *13*, 1698.
 https://doi.org/10.1038/s41467-022-29383-5.
- Weber, L. M., Nowicka, M., Soneson, C., and Robinson, M. D. (2019). diffcyt: Differential discovery in high-dimensional cytometry via high-resolution clustering. Communications Biology 2, 183. https: //doi.org/10.1038/s42003-019-0415-5.
- Van Gassen, S., Callebaut, B., Van Helden, M. J., Lambrecht, B. N., Demeester, P., Dhaene, T.,
 and Saeys, Y. (2015). FlowSOM: Using self-organizing maps for visualization and interpretation of
 cytometry data. Cytometry Part A *87*, 636–645. https://doi.org/10.1002/cyto.a.22625.
- Becht, E., McInnes, L., Healy, J., Dutertre, C.-A., Kwok, I. W., Ng, L. G., Ginhoux, F., and
 Newell, E. W. (2019). Dimensionality reduction for visualizing single-cell data using UMAP.
 Nature Biotechnology *37*, 38–44. https://doi.org/10.1038/nbt.4314.
- Lun, A. T., Richard, A. C., and Marioni, J. C. (2017). Testing for differential abundance in mass
 cytometry data. Nature Methods *14*, 707–709. https://doi.org/10.1038/nmeth.4295.
- Bruggner, R. V., Bodenmiller, B., Dill, D. L., Tibshirani, R. J., and Nolan, G. P. (2014). Automated
 identification of stratifying signatures in cellular subpopulations. Proceedings of the National
 Academy of Sciences *111*, E2770–E2777. https://doi.org/10.1073/pnas.1408792111.
- Polikowsky, H. G. and Drake, K. A. (2019). Supervised machine learning with CITRUS for single
 cell biomarker discovery. Mass Cytometry: Methods and Protocols, 309–332. https://doi.org/10.
 1007/978-1-4939-9454-0_20.

- Arvaniti, E. and Claassen, M. (2017). Sensitive detection of rare disease-associated cell subsets via
 representation learning. Nature Communications *8*, 14825. https://doi.org/10.1038/ncomms14825.
- 33. Jan, M. and Majeti, R. (2013). Clonal evolution of acute leukemia genomes. Oncogene 32, 135–
 140. https://doi.org/10.1038/onc.2012.48.
- 34. Rothenberg-Thurley, M., Amler, S., Goerlich, D., Köhnke, T., Konstandin, N. P., Schneider, S.,
 Sauerland, M. C., Herold, T., Hubmann, M., Ksienzyk, B., et al. (2017). Persistence of
 pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
 Leukemia, 1–27. https://doi.org/10.1038/leu.2017.350.
- Scandelli, T., Schneider, P., Garrido Castro, P., Jones, L. A., Bodewes, E., Rockx-Brouwer, D.,
 Pieters, R., Holstege, F. C., Margaritis, T., and Stam, R. W. (2022). Identification and
 characterization of relapse-initiating cells in MLL-rearranged infant ALL by single-cell
 transcriptomics. Leukemia *36*, 58–67. https://doi.org/10.1038/s41375-021-01341-y.
- 36. Turati, V. A., Guerra-Assunção, J. A., Potter, N. E., Gupta, R., Ecker, S., Daneviciute, A., Tarabichi,
 M., Webster, A. P., Ding, C., May, G., et al. (2021). Chemotherapy induces canalization of cell
 state in childhood B-cell precursor acute lymphoblastic leukemia. Nature Cancer 2, 835–852. https:
 //doi.org/10.1038/s43018-021-00219-3.
- Pan, L., Liu, G., Lin, F., Zhong, S., Xia, H., Sun, X., and Liang, H. (2017). Machine learning applications for prediction of relapse in childhood acute lymphoblastic leukemia. Scientific
 Reports 7, 1–9. https://doi.org/10.1038/s41598-017-07408-0.
- Mahmood, N., Shahid, S., Bakhshi, T., Riaz, S., Ghufran, H., and Yaqoob, M. (2020). Identification
 of significant risks in pediatric acute lymphoblastic leukemia (ALL) through machine learning (ML)
 approach. Medical & Biological Engineering & Computing, 1–10. https://doi.org/10.1007/s11517020-02245-2.
- 39. Mesegué, M., Alonso-Saladrigues, A., Pérez-Jaume, S., Comes-Escoda, A., Dapena, J. L.,
 Faura, A., Conde, N., Catalá, A., Ruiz-Llobet, A., Zapico-Muñiz, E., et al. (2021). Lower incidence
 of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli
 asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
 Hematological Oncology *39*, 687–696. https://doi.org/10.1002/hon.2914/v1/review2.
- 40. O'Neill, K., Aghaeepour, N., Špidlen, J., and Brinkman, R. (2013). Flow cytometry bioinformatics. PLoS Computational Biology 9, e1003365. https://doi.org/10.1371/journal.pcbi.1003365.
- Van Gassen, S., Gaudilliere, B., Angst, M. S., Saeys, Y., and Aghaeepour, N. (2020). CytoNorm:
 a normalization algorithm for cytometry data. Cytometry Part A 97, 268–278. https://doi.org/10.
 1002/cyto.a.23904.
- 42. Lee, G., Finn, W., and Scott, C. (2011). Statistical file matching of flow cytometry data. Journal of Biomedical Informatics *44*, 663–676. https://doi.org/10.1016/j.jbi.2011.03.004.
- 43. Law, C. W., Alhamdoosh, M., Su, S., Smyth, G. K., and Ritchie, M. E. (2016). RNA-seq analysis
 is easy as 1-2-3 with limma, Glimma and edgeR. F1000Research 5. https://doi.org/10.12688/
 f1000research.9005.3.
- 44. Stone, M. (1974). Cross-validatory choice and assessment of statistical predictions. Journal of the
 Royal Statistical Society: Series B (Methodological) 36, 111–133. https://doi.org/10.1111/j.2517 6161.1974.tb00994.x.
- 45. Cawley, G. C. and Talbot, N. L. (2010). On over-fitting in model selection and subsequent selection bias in performance evaluation. The Journal of Machine Learning Research *11*, 2079–2107.

 46. Jeni, L. A., Cohn, J. F., and De La Torre, F. (2013). "Facing imbalanced data–recommendations for the use of performance metrics". *2013 Humaine association conference on affective computing and intelligent interaction*. IEEE, 245–251. https://doi.org/10.1109/acii.2013.47.

Wainer, J. and Cawley, G. (2021). Nested cross-validation when selecting classifiers is overzealous
 for most practical applications. Expert Systems With Applications *182*, 115222. https://doi.org/10.
 1016/j.eswa.2021.115222.

48. Nowicka, M., Krieg, C., Crowell, H. L., Weber, L. M., Hartmann, F. J., Guglietta, S., Becher, B.,
Levesque, M. P., and Robinson, M. D. (2017). CyTOF workflow: differential discovery in
high-throughput high-dimensional cytometry datasets. F1000Research 6.
https://doi.org/10.12688/f1000research.11622.4.